A Study to Assess the Efficacy and Safety of ABTL0812

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

June 1, 2020

Study Completion Date

November 15, 2020

Conditions
Endometrial CancerSquamous Non-Small Cell Lung Cancer
Interventions
DRUG

ABTL0812 in combination with paclitaxel and carboplatin

ABTL0812 in combination with paclitaxel and carboplatin.

Trial Locations (1)

08290

Abilitypharma, Barcelona

Sponsors
All Listed Sponsors
collaborator

Hospital Vall d'Hebron

OTHER

collaborator

Institut Català d'Oncologia

OTHER

collaborator

Hospital Clínico Universitario de Valencia

OTHER

collaborator

Hospitales Universitarios Virgen del Rocío

OTHER

collaborator

Centre Leon Berard

OTHER

collaborator

Institut Paoli-Calmettes

OTHER

collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

lead

Ability Pharmaceuticals SL

INDUSTRY

NCT03366480 - A Study to Assess the Efficacy and Safety of ABTL0812 | Biotech Hunter | Biotech Hunter